Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

AdAlta signs agreement with FujiFilm Diosynth Biotechnologies to begin manufacturing its lead fibrosis drug candidate

AdAlta
Posted on: 13 Sep 16

MELBOURNE Australia, 12 September, 2016: AdAlta Limited (ASX: 1AD), the biotechnology company specialising in the discovery and development of protein-based therapeutics has entered an agreement with FujiFilm Diosynth Biotechnologies to manufacture AdAlta’s lead drug molecule for the treatment of idiopathic pulmonary fibrosis.

 

The agreement will see the process development, formulation and manufacture of AdAlta’s lead i-body molecule AD-114 by FujiFilm using its proprietary pAVEway™ advanced protein platform, an innovative technology for the production of proteins in bacteria, which has been proven in the expression of more than 90 biologics.

FujiFilm Diosynth Biotechnologies is one of the world’s leading global biologics and vaccines contract development and manufacturing organisations with development and manufacturing sites in Billingham (United Kingdom), North Carolina and Texas (United States) with over 1,000 employees.

Materials produced under the agreement at Fujifilm’s facility in Billingham in the United Kingdom will be used for animal and toxicology studies.

FujiFilm Diosynth Biotechnologies CEO Steve Bagshaw said, “We are looking forward to applying our versatile pAVEway™ expression system with such an innovative company as AdAlta with its unique i-body platform, and helping the company bring its novel biologic treatment, AD-114, to patients in need.”

AdAlta CEO Sam Cobb said, “The execution of this contract is an important step forward in the manufacture of our lead candidate. We have been impressed with the work already completed by the team at FujiFilm and expect to proceed rapidly with manufacturing of preclinical material for animal and clinical studies.”

For more information:
adalta.com.au/adalta-signs-agreement-fujifilm-diosynth-biotechnologies-begin-manufacturing-lead-fibrosis-drug-candidate

Editor's Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 13/09/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.